ACCESS ILD

We understand the challenges in Interstitial Lung Disease research

Interstitial lung disease research is constrained by fragmented data and limited access to well-characterized, longitudinal patient populations. ILD encompasses a heterogeneous group of rare and progressive conditions, yet studies often rely on small cohorts from specialist centres, with inconsistent phenotyping and short follow-up. This lack of scale, diversity, and real-world longitudinal insight hampers our ability to understand disease trajectories, identify meaningful sub-types, and evaluate treatment response - ultimately slowing the development of more effective and personalized therapies.

ACCESS ILD

uMed’s Access ILD Cohort

AccessILD addresses these challenges through a next-generation, remote cardiometabolic disease registry. Using electronic health record data, patients across the US and UK with a confirmed diagnosis are identified and invited to take. With consent, AccessCMD links routine clinical data with ongoing patient-reported outcomes and l genetic or biomarker data collected from home, creating a rich, longitudinal resource that enables inclusive research, patient stratification, and efficient recruitment for studies and clinical trials.

Get in touch

What is AccessILD

A next generation research platform.

High-touch patient communication is delivered by dedicated specialist nurse teams, ensuring participants receive personalised support and clear guidance throughout their involvement - ensuring excellent data completion, and without adding any operational or administrative burden to the patient’s existing healthcare providers.

Patient Website

Advisory Board

Anchored by leading scientific experts

Timothy Michael Dempsey

Chief Investigator

Timothy Michael Dempsey is a health care provider primarily located in Travis AFB, California in the United States. He specialises in Pulmonology, Critical Care Medicine, and Internal Medicine.

Prof. Phil Molyneaux

Cardiometabolic Advisory Chair

Phil is a Professor of Interstitial lung disease at Imperial College London. He is the Asthma+Lung UK Chair of Respiratory Research and Consultant in Interstitial lung disease at the Royal Brompton Hospital, where he is also the director of the NIHR Clinical Research Facility.

Prof. Nick Fuggle

Investigator

Turing Fellowship at the Alan Turing Institute. Numerous national and international awards, including the British Society of Rheumatology Young Investigator Award and the International Osteoporosis Foundation Pierre Meunier Award.

Security & Privacy

Setting a new standard for privacy & safeguarding

AccessILD is run and maintained by Cohort Science, a clinical research organization

HIPAA compliant data management, IRB-approved patient consenting and patient-centric study design